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Five patients had complete cadaveric small bowel 
transplants under FK506 immunosuppression, one as an 
isolated graft and the other 4 in continuity with a liver. 
Three were children and two were adults. The five 
patients are living 2-13 months posttransplantation 
with complete alimentation by the intestine. The typical 
postoperative course was stormy, with sluggish resump-
tion of gastrointestinal function. The patient with small 
intestinal transplantation alone had the most difficult 
course of the five, including two severe rejections, bac-
terial and fungal translocation with bacteremia, renal 
failure with the rejections, and permanent consignment 
to renal dialysis. The first four patients (studies on the 
fifth were incomplete) had replaeement of the lymphor-
eticular cells in the graft lamina propria by their own 
lymphoreticular cells. Although the surgical and after-
care of these patients was diffieult, the eventual uniform 
success suggests that intestinal transplantation has 
moved toward becoming a practical elinieal serviee. 
Until recently, death or graft loss after clinical intestinal 
transplantation usually was caused by failure to control rejec-
tion and/or the inability to prevent an attack on the host by 
graft lymphoid tissue (1). A stimulus for continued trials was 
provided in 1987 by the prolonged survival without rejection or 
GVHD of a patient whose functioning multivisceral graft con-
tained the entire small bowel and other intraabdominal hollow 
viscera (2). Using a variation of the multivisceral operation in 
which the liver and small intestine constituted the graft, Grant 
et al. (3) achieved complete rehabilitation of a 41-year-old 
woman who is still alive after 33 months (Personal communi-
cation, W. Wall, April 1991). These patients and a handful of 
others with isolated intestinal grafts (4-6) or short segments 
of duodenum and jejunum in cluster grafts (7,8) were treated 
with cyclosporine-based immunosuppression. 
In several animal intestinal transplant models (9-12), FK506 
has provided results superior to cyclosporine, prompting us to 
institute a clinical intestinal transplant trial. We report here 5 
consecutive cases-one with small intestinal transplantation 
alone and the other 4 with an intestine-liver combination. All 
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5 patients are alive after 2-13 months and nutritionally sup-
ported entirely by their intestinal grafts. 
MATERIALS AND METHODS 
Two of the recipients were young adults and 3 were children. Four 
of the 5 patients also had liver failure after 30-52 months of parenteral 
hyperalimentation. The recipient of the isolated intestine lost his small 
bowel 6 months before transplantation and still had good (although 
not normal) liver function. These and other features of the 5 cases are 
summarized in Table 1. 
The donors. The donors were ABO-identical with the recipient and 
were either size-matched (2 examples) or significantly smaller (Table 
2). HLA matching was random and uniformly poor (Table 2). Donor 
and recipient were the opposite sex in 3 of the 5 cases. The principles 
of the donor operations that allow flexibility of planning are described 
elsewhere (8). An attempt was made at selective bacterial decontami-
nation. Limited core cooling by aortic infusion of a limited amount 
(1000 ml maximum) of UW solution was used in all but one donor 
whose uninfused intestine was placed in an ice bath. No attempt was 
made to alter the graft lymphoreticular tissue with ALG or other 
modalities. In the last 3 cases, the contents of the intestine were 
entrapped by stapling the proximal jejunum and terminal ileum and 
carried with the specimen throughout the preservation and implanta-
tion; intraluminal washing was performed on the grafts for the first 2 
patients. 
Recipient operations. Vascularization: The technique for isolated 
intestinal transplantation was similar to that originally used by Lillehei 
et al. (13) in dogs more than 30 years ago, except that arterialization 
was with a free segment of donor iliac artery that was interposed 
between the superior mesenteric artery of the intestinal graft and the 
recipient aorta. In this case (patient 1), the distal stump of the recipient 
superior mesenteric vein was found after a tedious dissection and 
anastomosed to the graft SMV. 
The 4 liver-intestine transplantations varied in detail but followed 
the principles described elsewhere (8), which derived in turn from the 
experimental canine procedure of multivisceral transplantation (14). 
A typical reconstruction is shown in Figure 1, including the use of an 
interposition arterial graft that was used in all cases from the recipient 
aorta to the graft arterial supply. Other specific details of revasculari-
zation included (1) The use of the piggy-back venous outflow (15) in 
all 4 liver-intestine cases with preservation of the intrahepatic inferior 
vena cava; and (2) portacaval shunting prior to the anhepatic phase of 
the liver-intestine transplantations to prevent acute congestion of the 
residual splanchnic bed. The recipient portal vein was later detached 
and anastomosed to the portal vein or superior mesenteric vein of the 
allograft in 2 of the 4 patients, thereby assuring transhepatic delivery 
of pancreaticoduodenosplenic affluent from the native organ. In the 
other 2 patients, the portacaval shunt was retained permanently. The 
spleen had been removed at an earlier operation in one recipient. It 
was kept in 2 others and removed in the fourth in order to make more 
room for the liver-intestinal graft. 
Biliary drainage: No procedure was needed in the patient with 
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intestinal transplantation only. Biliary drainage for the liver-intestine 
recipients was through an isolated bowel conduit taken from the 
proximal end of the jejunum and emptied at a lower point into the 
jejunum (Fig. 1). 
Gastrointestinal reconstruction: Continuity was restored in stages 
in all 5 patients with construction of proximal (graft jejunostomy) and 
distal (ileostomy) vents (Fig. 1). Because end-to-side anastomoses to 
the duodenum (or jejunal stump) and colon (or, in one case, stump of 
ileum) were performed primarily (Fig. 1), the vents allowed early 
alimentation-or, alternatively, decompression on a moment-to-mo-
ment basis. Then 8-16 weeks later when intestinal motility was ade-
quate, the vent chimneys were excised at a second operation. 
Immunosuppression. FK506 was given intravenously at first, at 0.10-
0.15 mg/kg/day and enterally later at a starting dose of 0.3 mg/kg/day 
in divided doses, as described elsewhere for simple liver transplantation 
(16) (Figs. 2 and 3). Maintenance doses usually were lower. Prednisone 
was given at the outset in all but case 5 and later stopped in each of 
the children (Fig. 3). Drug therapy was changed from intravenous to 
enteral (Table 1) when jejunostomy feeding and ultimately oral intake 
were possible (Figs. 2 and 3). Patient 5 is still being fed and given oral 
medications through a nasogastric tube with its tip advanced into the 
graft jejunum. 
Management of immunosuppression was greatly facilitated by serial 
biopsies of both the upper and lower graft stomas, and of the liver in 
cases 2-5. These biopsies also were used for studying the graft lym-
phoreticular and epithelial phenotypes for their donor-recipient speci-
ficity as described elsewhere (17). 
Bacterial translocation. Frequent blood and stool cultures were ob-
tained and the results compared for similarity and dissimilarity of the 
flora. Selective decontamination was used for 4 weeks with a combi-
nation of polymyxin E, gentamycin/tobramycin, and mycostatin/am-
photericin B. Vancomycin was added at the time of positive blood 
cultures . 
Nutrition. Adequacy of intestinal function was judged principally by 
the ability to hold or gain weight, and to maintain serum protein 
concentrations. D-xylose absorption tests (18) were performed sporad-
ically. 
RESULTS 
Survival and hospitalization. The 5 patients are alive, and 
only the last one (2 months postoperatively) is in the hospital. 
The first 4 recipients were hospitalized for 4-9 months. pri-
marily because of difficulties in weaning from intravenous to 
enteral feeding. Restoration of reliable intestinal motility was 
slow, necessitating frequent switches from parenteral to enteral 
feeding and back before management could be stabilized. This 
required 8-36 weeks in patients 1-4. The longest interval of 36 
weeks was in the patient who received intestine alone (Table 
1). By the end of these times, all food and medications were 
given by the enteral route. The enteral doses of FK506 and 
steroids were not different from those in patients with liver 
transplantation alone (Figs. 2 and 3). 
Bacterial translocation_ Patients 1. 2, and 4 had the same 
microorganisms (Candida albicans, Enterococcus fecium/ Fe-
calis, cagula-negative Staphylococcus, and indifferent combi-
nations) in the intestine and blood simultaneously for 3-7 days 
at 2. 2.5, and 0.6 months postoperatively, respectively. Only 
one of these incidents was associated with rejection. 
Graft function. Liver: None of the recipients of the liver-
intestinal grafts (cases 2-5) has been jaundiced for more than 
a few days. However. patient 2 had continuous hypoalbumine-
mia «2 g%) until the third postoperative month. The cause 
was suspected to be the portacaval shunt used to drain the 
venous outflow of the recipient stomach, duodenum, and pan-
creas (Fig. 1, insert). However, the hypoalbuminemia (now 
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TABLE 2. Demographics of donors and recipients 
Patient Body weight (kg) Sex Blood type 
HLA" 
A B 
Solution for 
DR BW vucular 
perfusion 
Preservation of grafts" 
Solution for 
luminal ir-
rigation 
Cold ischemia 
time (hr) 
1 Recipient 86 M 0 28,31 35,51 2,5 4,6 
Donor 54 F 0 1,3 62,70 5 6 None LR 10.5 
2 Recipient 12.4 F 0 19,24 13,35 5,7 4,6 
Donor 12.0 F 0 2,28 57,60 6,7 4,6 UW LR 8.9 
3 Recipient 54.2 F B 2 7,55 2,5 6 
Donor 45.5 M B 2,30 7,18 I,ll 6 UW None 7.7 
4 Recipient 19.6 M A 1,2 44,57 4 
Donor 9.1 F A I,ll 8,35 3,4 6 UW None 2.9 
5 Recipient' 12.8 M 0 2,31 18,55 4,6 6 
Donor 13 M 0 2,34 44,45 2,8 4,6 UW None 10.6 
• Themonoc1onal antibodies in italics were used to identify HLA phenotypes of lymphocytes in peripheral blood and intestinal biopsies. 
• UW (University of Wisconsin solution), LR (lactated Ringer's solution). 
'Positive cytotoxic crossmatch with D'IT. 
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01 Portacaval shunt 
FIGURE 1. Liver plus small bowel transplantation. Native liver is 
replaced by the piggyback technique with the recipient's portal blood 
drainage into the graft portal vein or into the inferior vena cava (inset-
right). Two ends of the intestinal graft are exteriorized by chimney 
enterostomy at the left upper and right lower quadrant of the abdomen 
(inset-left) . 
>4g%) resolved without treatments and did not recur, despite 
an unequivocal hepatic rejection (confirmed by biopsy) at 176 
days. 
Patient 4 had transient jaundice at 3 months when rejection 
was diagnosed by liver biopsies. The jaundice resolved with 
increased immunosuppression. 
Intestine: After resuming full alimentation, all 5 intestinal 
to 120 '50 '10 210 2.0 31$ 
FIGURE 2. Clinical course of patient 1 who received an isolated 
small bowel graft. He had a stormy course in the immediate postoper-
ative period, with severe rejection, bacteremia and renal failure requir-
ing dialysis. (TPN, total parenteral nutrition; arrows = ACR (acute 
cellular rejection) and SM (solumedroll, boluses; SB, small bowel. 
recipients have either maintained or gained weight. Patient 1 
had a weight loss from 86 to 75 kg during the first 9 postoper-
ative months, but after diet was started and hyperalimentation 
stopped, weight stabilized and slowly increased. All other pa-
tients gained weight (Fig. 4). 
D-xylose absorption in the recipient of the isolated intestine 
(patient 1) was determined frequently and was normal until 
after a severe intestinal rejection at day 166. Three weeks later, 
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FIGURE 3. Clinical course of patient 2 who received a liver-plus-
small bowel graft. The first episode of intestinal graft rejection (POD 
18) was treated by augmentation of the FK dose. Note the rapid decline 
of the total bilirubin. 
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FIGURE 4. All but one patient gained body weight, from 5 to 21 %, 
at 2-10 months postoperatively. They are supported entirely by their 
intestinal transplants. 
absorption was severely depressed (Fig. 5, left). The latest D-
xylose absorptions in the first three liver-intestine recipients 
(cases 2-4) ranged from normal to slightly depressed (Fig. 5, 
right). 
Incidence of rejection. The diagnosis of rejection of either the 
intestine or liver was made histopathologically at the times 
indicated in Figures 2 and 3. Most of the biopsies (all summa-
rized in Table 3) were free of unequivocal rejection-and, even 
when present, the tissue diagnosis did not correlate well with 
clinical events unless the degree of rejection was classified as 
prominent. 
The most serious intestinal rejection was in the patient who 
received an intestine only (case 1). At 14 days, he became 
hypotensive and acidotic when both graft stomas turned cy-
anotic. Stomal biopsies showed severe rejection that was re-
versed with augmented FK506 and prednisone. At 166 days 
after transplantation after temporary discharge from the hos-
pital, and concomitant with drug noncompliance, he developed 
the same hypotensive syndrome and ileus. Endoscopy showed 
mucosal sloughing, and biopsies revealed severe rejection and 
intramural microabscesses. The process was reversed with im-
munosuppression. 
In the 4 recipients of a liver-intestine graft, both organs had 
relatively few diagnoses of unequivocal rejection (Table 3). 
Neither the liver nor the intestine appeared to be more or less 
favored relative to the other. 
Graft lympiwreticular repopulation. In the first four cases the 
HLA phenotypes of the lymphoid tissue of the lamina propria 
became those of the recipient after 54-86 days. During the 
same time, donor mononuclear cells were found in all of the 
recipients' peripheral blood. The details of these studies have 
been published elsewhere (17). Studies in patient 5 are still in 
progress. 
DISCUSSION 
This experience has demonstrated the inherent feasibility 
and practicality of small bowel transplantation in humans, a 
procedure which was first attempted in humans by Lillehei et 
a1. almost 25 years ago (19). As with the liver at an earlier time 
(20), the exploitation of intestinal transplantation awaited 
better immunosuppression before emancipation from the "for-
bidden" organ category. Liver transplantation became a service 
with the advent of cyclosporine, and now intestinal transplan-
tation may come into wide use because of FK506 whose quali-
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FIGURE 5. D-xylose absorption tests in 4 small bowel recipients. 
Absorption in patient 1 (left) was normal until 4 months postopera-
tively, but was suppressed shortly after when he had drug-noncompliant 
rejection at 166 days. D-xylose absorption in patients 2 and 3 was 
normal at 8-9 months postoperatively, and was satisfactory in patient 
4. Patient 5 has not been tested yet. 
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TABLE 3. Histological monitoring of graft rejection and treatment 
Histological degree of rejection Treatment of rejection [postoperative Number of days] Grafts biopsies 
None-to-minimal Mild Prominent Bolus Recycle OKT3 
Small bowel 17 21, 28, 58, 71, 78, 91, 7,36 14, 166 3 1 1 
126,150,176,195, [14,36, 166] [166] [14] 
215,245,378 
Small bowel 8 20,31,66,99, 224, 10,55, ll6 1 
[20] 
.;I.- . Liver 4 57,98,226 176 1 
,,' [230) K*K~: 
~D;D 3 Small bowel 8 10, 15, 56, 104, 107, 25,35 1 
t;· .- [35] 
,. 
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Liver 6 8, 15, 22, 39, 77, 236 4 
[11, 18, 107, 236] 
4 Small bowel 8 8, 10, 15, 43, 54, 114, 70 
166 
Liver 6 15 74, 167 79,88,112 4 
5 Small bowel 4 46,54 
Liver 4 21,23,46,54 
TABLE 4. Donor and recipient lymphocytes in peripheral blood and 
in the intestinal graft 
Patient 
1 
2 
3 
4 
Donor lymphocytes in peripheral 
blood 
Repopulation of recipient 
lymphocytes in small bowel 
graft 
Highest pro· 
portion (%) 
Postoperative days Postoperative Proportion of 
of disappearance days replacement (%) 
8.9 45 72 100 
11.6 54 86 100 
11.4 12 77 100 
ND" ND" 54 >80 
• Analysis not completed. 
ties have been shown by direct comparison to be superior to 
cyciosporine in rat intestinal transplant experiments (10, 11). 
Most of the other lessons from the early days of liver trans-
plantation appear also to be applicable to the intestine includ-
ing the infectious implications of rejection. With its rejection, 
the hepatic graft becomes a sieve for bacteria translocated from 
the intestine (21, 22). Paradoxically, such hepatic graft based 
infections could be prevented or treated only by the heavier 
immunosuppression that itself contributes to systemic suscep-
tibility to infection. The therapeutic philosophy of preventing 
bacterial translocation in this way is even more applicable to 
the intestinal graft in which the foremost requirement is main-
tenance of an intact mucosal barrier. Using cyclosporine-based 
immunosuppression in multivisceral recipients, it was not pos-
sible to interdict bacterial leakage, with the consequence that 
there was repeated bacteremia or fungemia with the same 
microorganisms found in the intestinal content (2). Of the 5 
presently reported patients under FK506, 3 had this complica-
tion, but it could be controlled with adjustments of immuno-
suppression combined with efficient antibiotic treatment. 
Prevention of GVHD is also dependent upon highly effective 
immunosuppression. Clinical GVHD was not seen in any of 
our 5 recipients despite severe histoincompatibility and the 
appearance of donor mononuclear cells in the peripheral blood 
of all (17). At the same time, the lymphoreticular cells in the 
11 
[11,82,118, 120] 
20 2 
[11,21] 
lamina propria of the graft were being replaced by lymphore-
ticular cells of the recipient. Rapid cell migration and repopu-
lation of lymphoreticular cells in chronically tolerated piglet 
intestinal grafts under cyclosporine were noted by Arnaud-
Battandier et a1. (23) in 1985, and by Jaffe et a1. (24) in the 
intestinal component of a multivisceral graft that also was the 
site of lymphoproliferative lesions of recipient origin. Clark et 
al. (25) and Lear et al. (26) showed striking cell migration in 
rat intestinal recipients. 
In most of these reports, the cell repopulation was equated 
more with rejection or GVHD than with graft acceptance (24-
26). The significance of the cell repopulation phenomenon and 
its indispensability for graft acceptance was first described by 
Murase et a1. in rats (12) and by Iwaki et al. in the first 3 
patients of the present human series (17). By this process, the 
transplanted intestine becomes a "composite" organ within a 
few weeks but with retention of donor-specific epithelium. 
Studies are in progress to learn the fate of the donor lym-
phoreticular cells that leave the graft and enter the circulation. 
Lear et a1. (26) described the major movement of passenger 
(presumably T) cells into thymus-dependent host lymphoid 
tissue, and warned that GVHD could actually be promoted by 
effective immunosuppression that would allow these cells to 
become established. The phenomenon of donor cell peripher-
alization and replacement with recipient cells is probably ge-
neric, occurring in all kinds of grafts, although it is most easily 
studied in the intestine because of the intestine's rich lymphoid 
constituency. For example, macrophage repopulation of the 
liver has been known for almost two decades (27) and similar 
replacement of the lymphoreticular cells has been described in 
heart-lung grafts (28). 
What was made clear by Murase's rat experiments (12) and 
by Iwaki's study of the presently reported patients (17) is that 
the relocated cells can be functionally inert, causing neither 
rejection nor GVHD, provided that the conditions of induction 
and maintenance immunosuppression are propitious. We have 
speculated that the cell exchange occurs most reliably in the 
presence of a normal microenvironment. If so, we have pointed 
out that the common practices may be ill-conceived, damaging 
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the graft lymphoid deposits with irradiation, antilymphoid 
globulins, chemotherapy, or other measures (8). No such graft 
pretreatment was employed in any of our 5 cases. 
Even at a technical surgical level, other widely accepted 
assumptions about intestinal transplantation come into ques-
tion. For example, the preservation of the intestine was with 
an extremely simple technique in which the graft was cooled 
by immersion in an ice bath, or with just enough intraarterial 
UW solution to cause blanching of the capillary bed. Instead 
of washing out the succus entericus of the intestine, this was 
kept with the specimen throughout in 3 of the 5 cases by 
stapling shut the intestinal graft at the upper and lower ends. 
There were no consequent infections from this practice. 
In the recipient an attempt was made to restore normal 
anatomic relationships between the residual recipient organs 
and the transplanted or native liver, and above all to direct the 
venous affluent from the pancreas, intestine, and other splanch-
nic viscera through the retained or concomitantly engrafted 
new liver. The complex metabolic and immunologic interrela-
tionships of the various intraabdominal organs are discussed 
elsewhere (8,29). 
The function of the transplanted intestine alone or with 
accompanying liver has been satisfactory in all five patients, 
with eventual complete independence from parenteral nutri-
tion. Since resuming full alimentation, all 5 patients have 
maintained (1 case) or gained weight (4 cases). Reliable absorp-
tion studies with D-xylose were difficult to obtain under these 
clinical circumstances, and the results did not correlate well 
with common-sense clinical assessments of the state of nutri-
tion. 
The achievement of alimentation was a slow process, requir-
ing from 6 weeks to 9 months. By the time this was achieved, 
the doses of oral FK506, steroids, and other medications were 
in the same range as with other kinds of transplantation, 
indicating the efficient absorption of these medications. Earlier 
in the postoperative course, the transplanted and denervated 
intestine was prone to ileus, making it essential to have proxi-
mal and distal enteric vents either for decompression or as an 
entry for graded feedings. There are theoretical reasons for 
early resumption of alimentation, but practical reasons for 
doing this with extreme caution. 
The question remains whether intestinal transplantation 
alone is a more or less difficult procedure than combined liver-
intestine transplantation. The experimental work of Murase et 
al. (12, 30) and others (8) has supported the concept that the 
liver may shield the intestine from immunologic attack, but 
this advantage is relative only. The long survival of patient 1 
in our series and that of the recipients of DeItz et al. (6) and 
Ricour and Goulet et al. (5) have demonstrated the feasibility 
of the technically less draconian procedure of isolated intestinal 
transplantation. 
In our patient 1, severe but reversible rejection after 2 weeks 
and again at 5112 months after isolated small bowel transplan-
tation caused a shock syndrome, with a third space fluid accu-
mulation in the graft, as well as bacteremia and candidemia 
that led to permanent secondary loss of renal function. How-
ever, the intestinal changes were reversible, including healing 
and regeneration of ulcerative and sloughed intestinal epithe-
lium. The power of the reparative process has been seen even 
more dramatically in a duodenal jejunal intestinal segment that 
was part of an upper abdominal cluster graft that recovered to 
a normal state after being almost completely denuded of epi-
thelium as a consequence of rejection (8, 31). 
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ORAL DISCUSSION 
DR. A. LANGNAS (Omaha, Nebraska): You indicated that 
there were a number of episodes of bowel rejection. How did 
you document and classify this? How did you adjust your 
therapy? 
DR. TODO: The most important diagnostic tool for the small 
bowel recipient is the inspection of the stoma. Cyanotic change 
is the first sign of rejection. When this is noted, we perform 
endoscopy through the stoma to obtain biopsy material for 
histologic confirmation. Later, after the stomas have been 
closed the situation might be more difficult-however, we have 
observed only one episode of rejection in that setting. This 
patient had an episode at 166 days, the result of drug-noncom-
pliance. He had severe abdominal pain and diarrhea. At colon-
oscopy we saw sloughing of the mucosa, and biopsy showed the 
denuding of the mucosal layers. 
DR. LANGNAS: Have you seen any findings in the submu-
cosa such as the vasculitis described in a number of small 
animal models? 
DR. TODO: Yes, we observed slight arteritic changes in the 
intestinal wall in one patient when a biopsy was taken at the 
operation for stomal closure about 4 months after transplan-
tation. 
DR. ALSINA (Hartford, Connecticut): I would like to know 
if you are planning to use portal venous drainage in the future. 
The issue as to whether this is beneficial or necessary has not 
been settled. I also have a comment. We have finished a small 
bowel transplant study in outbred pigs and have observed more 
graft-versus-host reaction in the native tissues when using very 
low doses of cyclosporine in combination with azathioprine and 
prednisone. 
DR. TODO: Responding to your comment first, in our labo-
ratory we also saw the GVH disease when the animals were 
treated with subtherapeutic immunosuppression, but we didn't 
see any GVH diseases in our five clinical small bowel recipients. 
Concerning the first question, we believe that venous drainage 
from the graft should be with a portal anastomosis, since it is 
physiological and may also have metabolic and immunological 
advantages. 
DR. HARDY (New York, New York): I wonder whether you 
could comment on two issues: One is the question that you 
alluded to suggesting a certain exchange in migration of lym-
phocytes' so that the donor lymphocytes end up in the blood 
and recipient lymphocytes end up in the small bowel, an ex-
pected phenomenon. A recent article by your group suggested 
that there is some magic about this in terms of protection of 
the bowel. Perhaps you could comment on those observations 
in relation to other people's experience with pretreating the 
donor in clinical situations with massive doses of antilymphoid 
preparations. and in experimental situations with various an-
tilymphoid drugs, as well as low-dose radiation. My second 
question concerns GVHD. We all know that a small amount of 
graft-versus-host disease may help the graft to survive. You 
have an excellent model for studying this in men. Does it help? 
DR. TODO: Although exchange of donor and recipients 
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could have been expected, this phenomenon was 
i>C1~en1;ea clinically only recently in hepatic and small bowel 
iDograi!ts by our group and the Canadian group. This suggests 
prb~trb~atlmelnt of the donor or small bowel graft to avoid 
disease is probably unnecessary. However, we do not 
the value of pretreatment as a strategy to reduce graft 
iaJIugenJlclt:y, such as by passenger leukocyte depletion-this is 
current laboratory interest. 
DR. D. GRANT (London Ontario Canada): We have three 
· patients who are well with liver-small bowel grafts at two and 
· half years, one and a half years, and three months after trans-
p .. nrli~lrDllK These patients were treated with cyclosporine. I'm 
· wondering if you think that your success is due to the combined 
)iver graft, or whether you think it's due to the potency of 
FK506. Are you prepared to proceed with isolated small bowel 
... srafting using the FK506? 
· DR. TODO: Regarding successful combined liver and small 
bowel graft, I think both factors contributed to the result. As 
,. you described in the Lancet, and has been described also by our 
group and others, the liver seems to have a protective effect on 
other organs when transplanted together. The potency of 
FK506 should not be ignored, since 2 out of 5 recipients were 
treated virtually only with FK506. We plan more isolated small 
bowel transplantations using FK506; we additionally have sev-
eral ongoing animal studies designed to support the clinical 
program. 
DR. HARDY: Dr. Grant, do you still pretreat your donors 
with massive doses of OKT3 or a similar preparation? 
DR. GRANT: We have, but I'm not sure that it is necessary. 
DR. FRANK GUTTMAN (Montreal, Quebec, Canada): I 
would like to comment on the liver-small bowel experience in 
rats. I was privileged a few weeks ago to see a manuscript from 
Revillon's group in Paris. They have the experience of nine 
clinical small bowel transplantations in children. They have 
completed a study in a rat combination where the liver is 
accepted between the two strains without any immunosuppres-
sion, but the bowel is not. However, if they do a liver transplant 
and 17 days later carry out a bowel transplant, again without 
immunosuppressive drugs, tolerance of the small bowel was 
observed. 
DR. HARDY: Can you identify the specific rat combina-
tions? 
DR. GUTTMAN: It was RtlA and C or 0, something like 
that. 
DR. HARDY: This phenomenon, protection by the liver, has 
in many instances been rat-specific. I would warn those who 
wish to repeat the experiment to be aware of the specific shown 
combinations. 
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LIVER TRANSPLANTATION FOR PRIMARY HEPATIC CANCER! 
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Although early survival following transplantation for 
primary hepatic cancer is excellent, previously reported 
high recurrence rates have generally discouraged liver 
replacement for this indication. Since the inception of 
the Boston Center for Liver Transplantation (BCLT) in 
1983, 33 of 383 (8.6%) liver allograft recipients have 
undergone orthotopic transplantation as definitive 
treatment for otherwise unresectable cancer. 
Diagnoses included hepatocellular carcinoma (HCCA) 
in 24 patients (73%), and cholangiocarcinoma (CHCA) 
in 9 patients (27%). Actuarial survival rates for patients 
with hepatocellular carcinoma were 71 %,56%, and 42% 
at I, 2, and 3 years, respectively. The actuarial survival 
rates for patients with cholangiocarcinoma were 89% at 
6 months, and 56% at I, 2, and 3 years. Of the nine 
patients with cholangiocarcinoma, 56% (5/9) developed 
recurrent disease. Although this recurrence rate is dis-
heartening, because of the lack of other morbidity, long-
term survival in these patients is comparable to patients 
with HCCA. In contrast, recurrent hepatocellular car-
cinoma developed in 25% of recipients (5/20) who sur-
vived longer than 3 months posttransplantation. Other 
causes of death in patients with hepatocellular carci-
noma included perioperative complications, 16.6% (4/ 
24); sepsis, 8.3% (2/24); coronary artery disease, 4.2% 
(1/24); and lymphoma, 4.2% (1/24). Favorable prognos-
tic factors included: primary tumor <3 cm in size and 
absence of associated cirrhosis. 
These results emphasize that orthotopic liver trans-
plantation can provide a 10ng-teJ:"m cure for approxi-
mately 50% of patients whose primary hepatic malig-
nancy is unresectable by conventional procedures. 
1 Presented at the 17th Annual Meeting of the American Society of 
Transplant Surgeons, May 29-31,1991, Chicago, IL. 
2 Massachusetts General Hospital. 
3 New England Deaconess Hospital. 
4 New England Medical Center Hospital. 
Primary malignancy of the liver can be treated by conven-
tional hepatic resection in only 20-40% of cases (1-3). When 
hepatic neoplasms are unresectable, the median survival from 
the time of diagnosis is only 2-4 months since no effective 
nonsurgical therapeutic regimen has yet been identified. For 
this reason, total hepatectomy and liver replacement were 
embraced early on as a natural extension of partial hepatectomy 
in instances where the carcinoma, although confined to the 
liver, was either too extensive or the associated cirrhosis too 
advanced to permit excision while still leaving sufficient hepatic 
reserve. Not only did complete hepatectomy conform more 
closely to Halsted's principles of cancer resection, but the 
operation actually proved (technically) relatively easy so that 
early results were better than those achieved following trans-
plantation in patients with end-stage cirrhosis and its coexist-
ing multisystem complications (4). 
Unfortunately, although early posttransplantation survival 
was excellent, longer-term success was quite limited. Even 
tumor seemingly confined to the liver proved likely to recur 
within 2 years of transplantation (5). While this deflated the 
initial enthusiasm accorded transplantation for primary liver 
cancer, there remained several positive features: (1) in general, 
survival was still better than that achieved with partial resec-
tions ± chemotherapy (6, 7); (2) consistently, some patients 
achieved a "cure"; and (3) there was some correlation between 
outcome and stage of disease, which emphasized that more 
appropriate selection of suitable candidates for the procedure 
should provide more satisfactory results (8, 9). 
Palliation with little expectation of cure historically has been 
a sufficient indication to justify many medical treatments. 
Nevertheless, the criteria are more stringent for high-technol-
ogy procedures such as orthotopic liver transplantation. Liver 
transplantation is a highly visible undertaking with a large up-
front expense, time commitment, and more widespread appli-
cability limited by inadequate numbers of donor organs. Thus, 
the natural conclusion might be that liver transplantation 
